3 ADPP i state cannot be distinguished from the ATP state by NMR, precluding categorization of the mutant
The compound was developed in the late 1990s by Novo Nordisk and characterised in a 1998 paper as the first selective GH secretagogue, meaning it stimulated GH release without the prolactin, ACTH, cortisol, or aldosterone elevations seen with earlier GHRPs
This has been a complaint for many patients taking GLP-1s who are not comfortable or afraid of needles and wary of the idea of administering the injections themselves
The results are promising
(PubMed) Bowman GL, Dodge H, Frei B, et al
Third-Party Testing Has the product been tested for banned substances by Informed Sport, NSF, or Banned Substance Control Group (BSCG)